Skip to main content
SpringerLink
Log in

Dopaminergic Agents in Heart Failure: Rebirth of An Old Concept

  • Editorial Introduction
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rajfer SI, Anton AH, Rossen JD, Goldberg LI. Beneficial hemodynamic effects of oral levodopa in heart failure. NEngl J Med 1984; 310: 1357-62.

    Google Scholar 

  2. Rajfer SL, Rossen JD, Douglas FL, Goldberg LI, Karrison T. Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: Relationship to the generation of Dopaminergic Agents in Heart Failure 109 N-methyldopamine and to plasma norepinephrine levels. Circulation 1986; 73: 740-48.

    Google Scholar 

  3. Shah PK, Amin DK, Horn E. Adverse clinical and hemodynamic effects of oral levodopa in chronic congestive heart failure. Am Heart J 1985; 110: 488-89.

    PubMed  Google Scholar 

  4. Rajfer SK, Rossen JD, Nemanich JW, Douglas FL, Davis F, Osinski S. Sustained hemodynamic improvement during long-term therapy with levodopa in heart failure; Role of plasma catecholamines. J Am Coll Cardiol 1987; 10: 1286-93.

    PubMed  Google Scholar 

  5. Missale C, Metra M, Sigaaala S, Memo M, Dei Cas L, Spano PF. Inhibition of aldosterone secretion by dopamine, ibopamine and dihydroergotoxine in patients with congestive heart failure. J Cardiovasc Pharmacol 1989; 14(suppl 8): S72-76.

    Google Scholar 

  6. van Veldhuisen DJ, Man in 't Veld AJ, Dunselman PHJM, et al. Double-blind, placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: Results of the Dutch Ibopamine Multricentre Trial (DIMT). J Am Coll Cardiol 1993; 22: 1564-73.

    PubMed  Google Scholar 

  7. Hampton JR, van Veldhuisen DJ, Kleber FX, et al. For the Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Randomised study of effect of ibopamine on survival in patients with advanced heart failure. Lancet 1997; 349: 971-77.

    PubMed  Google Scholar 

  8. Remme WJ. Positive inotropic therapy: Dead end or new horizon? J Cardiac Failure 1996; 2(4S): S267-76.

    Google Scholar 

  9. van der Ent M, van den Heuvel AFM, Remme WJ. Neurohormonal response to carmoxirole, a selective dopamine (D2) receptor agonist, in patients with chronic moderate heart failure. Cardiovasc Drugs Ther 1998; 12: 387-94.

    PubMed  Google Scholar 

  10. Masson S, Chimenti S, Salio M, et al. CHF-1024, a DA2/α 2agonist, blunts norepinephrine excretion and cardiac fibrosis in pressure overload. Cardiovasc Drugs Ther 2001; 15: 131-139.

    PubMed  Google Scholar 

  11. Tjeerdsma G, vanWijk LM, Molhoek GP, Boomsma F, Haaksma J, van Veldhuisen DJ. Autonomic and hemodynamic effects of anewselective dopamine agonist,CHF1035, in patients with chronic heart failure. Cardiovasc Drugs Ther 2001; 15: 139-147.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sticares Cardiovascular Research Foundation, Rhoon, The Netherlands

    Willem J. Remme

Authors
  1. Willem J. Remme
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Remme, W.J. Dopaminergic Agents in Heart Failure: Rebirth of An Old Concept. Cardiovasc Drugs Ther 15, 107–109 (2001). https://doi.org/10.1023/A:1011162510450

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011162510450

Search

Navigation